Novel transcript, antisense to ACAP2 (ENSG00000295476)

This molecule is a natural antisense transcript (NAT) expressed opposite to the ACAP2 gene. NATs are endogenous RNAs complementary to sense transcripts of protein-coding genes. They primarily act through regulatory mechanisms such as transcriptional interference, RNA masking, modulation of chromatin structure, and can impact processes like splicing, gene silencing, and stability of the sense mRNA[3][4][5]. In many cases, such antisense RNAs do not encode proteins and their biological function can range from fine-tuning gene expression to mediating epigenetic effects. While NATs as a class can affect disease states indirectly through regulation of their sense partners, this specific transcript has not been characterized as a direct therapeutic target, nor does it have established interactions with drugs or diagnostic biomarkers[1][3][5].\n\nKey contextual notes:\n- The transcript’s status and annotation reflect the ongoing cataloging of noncoding RNAs in the human genome[3].\n- Noncoding antisense RNAs are an active area of study, but reliable, actionable pharmacological information about individual NATs is rare unless functionally characterized[1][4].\n\nThere is no evidence from current search results that “novel transcript, antisense to ACAP2” (ENSG00000295476) is a receptor, enzyme, transporter, diagnostic, or direct drug target. Its entry represents a noncoding RNA, not a canonical therapeutic target.

Other names

ACAP2-antisense RNAACAP2 NAT

Not applicable; NATs may regulate targets via transcriptional interference, RNA masking, dsRNA-dependent RNA interference, or chromatin remodeling. This transcript is not known to be modulated pharmacologically.